Retinal Disease Therapeutics Market 2019: Company Profiles, Emerging Technologies, Trends, Industry Growth, Segments, Landscape and Demand by Forecast to 2025 - Reuters

 

Retinal Disease Therapeutics Market 2019: Company Profiles, Emerging Technologies, Trends, Industry Growth, Segments, Landscape and Demand by Forecast to 2025

Retinal Disease Therapeutics Market 2019: Company Profiles, Emerging Technologies, Trends, Industry Growth, Segments, Landscape and Demand by Forecast to 2025

Fri Jun 14, 2019 - 10:30am UTC

Global Retinal Disease Therapeutics Market to Reach US$ 21,318.0 Mn by 2026, Advancements in Retinal Disease Diagnosis Devices to Boost the Market, says Fortune Business Insights

pune, India – June 14, 2019

The global retinal disease therapeutics market is likely to expand at an impressive rate driven by recent government participation towards the prevention and control of retinal diseases. According to a report published by Fortune Business Insights, titled “Retinal Disease Therapeutics: Global Market Analysis, Insights, and Forecast, 2019-2026,” the market is likely to reach US$ 21,318.0 Mn by the end of 2026. The market was valued at US$ 11,044.2 Mn in 2018 and is likely to witness a CAGR of 8.6% in the forecast period.

Get PDF Brochure of this Report@ https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/retinal-disease-therapeutics-market-100311

F. Hoffmann-La Roche AG’s ‘Lucentis’ is Gaining Increasing Popularity
The global retinal disease therapeutics market is consolidated in nature, with only a handful of market players accounting for maximum share of the market. With consolidation, it is becoming increasingly difficult for newer market entrants to establish a stronghold or derive immediate success.

Introduction
• Merck & Co., Inc.
• Novartis AG
• Allergan plc
• F. Hoffmann-La Roche AG
• Regeneron Pharmaceuticals, Inc.
• Santen Pharmaceutical Co., Ltd.

Top Players Overview:
• Merck & Co., Inc.
• Novartis AG
• Allergan plc
• F. Hoffmann-La Roche AG
• Regeneron Pharmaceuticals, Inc.
• Santen Pharmaceutical Co., Ltd.

Therefore the global market is boosted by products and concepts introduced by existing companies. One such instance of this development is the “Lucentis” therapy, put forward by F. Hoffmann-La Roche AG. Lucentis was introduced with the aim of providing therapeutic advice and the development of products for patients suffering from chronic disease. In 2017, the Food and Drug Administration (FDA) approved Lucentis for diabetic retinopathy.

Regional Analysis:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

The diabetic retinopathy is a severe kind of disorder that has accounted for majority of cases of blindness in the US. Lucentis was an instant hit among healthcare professionals after it was backed by a series of clinical trials and aprovals from the National Institute of Health (NIH). Excellent clinical effects of Lucentis have led to a subsequent rise in demand for the medicine among patients. The increasing demand has contributed to the growth of the global retinal disease therapeutics market and is likely to favor the market in the forthcoming years.

Request Customization of this Report@ https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/retinal-disease-therapeutics-market-100311

North America to Emerge Dominant in the Forecast Period

The increasing government investment towards research and development of retinal disease drugs and diagnostic devices is enabling growth in the retinal diseases therapeutics market in North America. North America has emerged dominant in the global retinal disease therapeutics market in recent years.
The retinal disease therapeutics market in North America was valued at US$ 4056.5Mn in 2018 and is likely to increase in the coming years. Improved health infrastructures, increasing patient pool, and favorable health reimbursement policies are some of the factors that are likely to boost the regional market in the forthcoming years. The high prevalence of retinal diseases in the Asia Pacific is a major reason, why this region is estimated to rise with the highest CAGR in the forecast period.
Some of the leading companies that are operating in the global retinal disease therapeutics market are Merck & Co., Inc., Novartis AG, Allergan plc, F. Hoffmann-La Roche AG, Regeneron Pharmaceuticals, Inc., and Santen Pharmaceutical Co., Ltd.

Browse Full Report@ https://www.fortunebusinessinsights.com/industry-reports/retinal-disease-therapeutics-market-100311

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Info:
Name: Ankit Dwivedi
Email: Send Email
Organization: Fortune Business Insights Pvt. Ltd.
Address: 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune – 411045, Maharashtra, India.
Phone: +1 424 253 0390
Website: https://www.fortunebusinessinsights.com/industry-reports/retinal-disease-therapeutics-market-100311

This content is not produced by Reuters Editorial News. It is produced by VC NewsNetwork. For content enquiry, please reach us at

Latest News >

Arbor Ventures to co-lead US$15 million Series A in US Data Residency Compliance Firm InCountry

This funding round highlights the importance of global data protection in businesses and an overwhelming market demand triggered by the growing challenges of companies in expansion.

03:46am UTC

Corporate travel startup receives US$3M pre-Series A funding

The Singaporean startup is one of its kind in the Southeast Asian leisure-oriented travel industry.

08:22am UTC

Singapore’s AI Intelligence Platform secures US$100 million to offer new data suites

Near plans to use the funding capital to launch a new suite of data products and expand into strategic markets including Australia and the US.

08:11am UTC

IDN Media acquires Indonesian eSports media GGWP.ID

This marks IDN Media’s first foray into the eSports scene in Indonesia.

09:33am UTC

MHomecare is the Winner of Indonesia-Korea Startup Demo Day 2019

MHomecare is a platform that provides on-demand homecare services in Indonesia.

03:09am UTC